Failure of azithromycin 2.0 g in the treatment of gonococcal urethritis caused by high-level resistance in California

Sexually Transmitted Diseases

Volumn 42, Issue 5, 2015, Pages 279-280

  Gose, Severin O ^a   Soge, Olusegun O ^b   Beebe, James L ^c   Nguyen, Duylinh ^a   Stoltey, Juliet E ^d   Bauer, Heidi M ^d  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Public Health Laboratory San Luis Obispo Department of Public Health   (United States)

^d NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; DOXYCYCLINE; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; DRUG TREATMENT FAILURE; GONOCOCCAL URETHRITIS; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; YOUNG ADULT; CONTACT EXAMINATION; DRUG EFFECTS; EPIDEMIOLOGY; FEMALE; GENETICS; GONORRHEA; HEALTH SURVEY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NEISSERIA GONORRHOEAE; TREATMENT FAILURE; URETHRITIS;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CALIFORNIA; CEFTRIAXONE; CONTACT TRACING; DRUG RESISTANCE, BACTERIAL; FEMALE; GONORRHEA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; POPULATION SURVEILLANCE; TREATMENT FAILURE; UNITED STATES; URETHRITIS;

EID: 84928545454     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000265     Document Type: Article

References (19)

1. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard. CLSI document M07-A9 Villanova, PA: NCCLS, 2012
2. Soge OO, Harger D, Schafer S, et al. Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011). Sex Transm Dis 2012; 39:877-879
3. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Fourth Informational Supplement. CLSI document M100-S24 Wayne, PA: Clinical and Laboratory Standards Institute, 2014
4. Katz AR, Komeya AY, Soge OO, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: Case report of the first isolate identified in the United States. Clin Infect Dis 2012; 54:841-843
5. Kirkcaldy RD,WeinstockHS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 2014; 59:1083-1091
6. Martin IMC, Ison CA, Aanensen DM, et al. Rapid sequence-based identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004; 189:1497-1505
7. Ng L-K, Martin I, Liu G, et al. Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2002; 46:3020-3025
8. Luna VA, Cousin S, Whittington WL, et al. Identification of the conjugative mef gene in clinical Acinetobacter junii and Neisseria gonorrhoeae isolates. Antimicrob Agents Chemother 2000; 44:2503-2506
9. Gose S, Nguyen D, Lowenberg D, et al. Neisseria gonorrhoeae and extended-spectrum cephalosporins in California: Surveillance and molecular detection of mosaic penA. BMC Infect Dis 2013; 13:570
10. Allen VG, Seah C, Martin I, et al. Azithromycin resistance is coevolving with reduced susceptibility to cephalosporins in Neisseria gonorrhoeae in Ontario, Canada. Antimicrob Agents Chemother 2014; 58:2528-2534
11. Palmer HM, Young H, Winter A, et al. Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland. J Antimicrob Chemother 2008; 62:490-494
12. Chisholm SA, Neal TJ, Alawattegama AB, et al. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother 2009; 64:353-358
13. Chisholm SA, Dave J, Ison CA. High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob Agents Chemother 2010; 54: 3812-3816
14. Galarza PG, Alcalá B, Salcedo C, et al. Emergence of high level azithromycin-resistant Neisseria gonorrhoeae strain isolated in Argentina. Sex Transm Dis 2009; 36:787-788
15. Galarza PG, Abad R, Canigia LF, et al. New mutation in 23S rRNA gene associated with high level of azithromycin resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2010; 54:1652-1653
16. Zarantonelli L, Borthagaray G, Lee EH, et al. Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. Antimicrob Agents Chemother 1999; 43:2468-2472
17. Lewis DA. The role of core groups in the emergence and dissemination of antimicrobial-resistant N gonorrhoeae. Sex Transm Infect 2013; 89 (suppl 4):iv47-iv51
18. Kirkcaldy RD, Soge O, Papp JR, et al. Analysis of Neisseria gonorrhoeae azithromycin susceptibility in the United States by the Gonococcal Isolate Surveillance Project, 2005 to 2013. Antimicrob Agents Chemother 2015; 59:998-1003
19. California Department of Public Health. Gonorrhea Treatment and Management of Suspected Treatment Failure.Available at: http://www. cdph.ca.gov/programs/std/Documents/CA-GC- Treatment- Failure- Protocol.pdf. Accessed October 30, 2014